{
  "abstract": "Background and Importance AMD and DME are leading causes of vision loss, with ranibizumab and aflibercept as key treatments. However, frequent monthly injections create a significant burden on healthcare systems and patients. While clinical trials provide standard dosing, real-world data on treatment frequency is limited. This study aims to assess visit frequencies and their impact on healthcare resources, with the goal of optimising treatment intervals to reduce strain while maintaining efficacy.Aim and Objectives Ranibizumab and aflibercept are indicated, among others, for the treatment of adult patients with age-related macular degeneration (AMD) and visual impairment due to diabetic macular oedema (DME). This study aimed to analyse the frequency of patient visits to achieve therapeutic effects for both treatments in these indications, assessing the workload and optimising resource management.Material and Methods This was a retrospective observational study included patients treated for AMD and DME with ranibizumab and aflibercept over one year (January 2024 to December 2024). Dispensing data from the pharmacy was reviewed, and patients were categorised by administration frequency: monthly, every month and a half, bimonthly, quarterly, and every four months, following the ‘treat and extend’ regimen.Results A total of 529 AMD and 261 DME patients were analysed. In AMD, 276 patients were treated with aflibercept and 253 with ranibizumab; for DME, 138 received aflibercept and 123 ranibizumab.Conclusion and Relevance The frequency of visits is similar for both treatments in AMD and DME. To achieve therapeutic outcomes, patients must attend consultations with a frequency of less than or equal to 1 month for both indications. While clinical trials provide important data, only real-world evaluations can ensure the effective implementation of results. Given the high percentage of monthly visits observed, an appropriate option would be to explore longer intervals of efficacy or to seek therapeutic alternatives that allow for spacing out dosesConflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "Hospital Morales Meseguer, Hospital Pharmacy, Murcia, Spain"
      ],
      "name": "A Martinez Orea"
    },
    {
      "affiliations": [
        "Hospital Morales Meseguer, Hospital Pharmacy, Murcia, Spain"
      ],
      "name": "M Guillen Diaz"
    },
    {
      "affiliations": [
        "Hospital Morales Meseguer, Hospital Pharmacy, Murcia, Spain"
      ],
      "name": "A Sanchez Blaya"
    },
    {
      "affiliations": [
        "Hospital Morales Meseguer, Hospital Pharmacy, Murcia, Spain"
      ],
      "name": "C Portero"
    },
    {
      "affiliations": [
        "Hospital Morales Meseguer, Hospital Pharmacy, Murcia, Spain"
      ],
      "name": "E Palazon Golzalvez"
    },
    {
      "affiliations": [
        "Hospital Morales Meseguer, Hospital Pharmacy, Murcia, Spain"
      ],
      "name": "R Alegria Samper"
    },
    {
      "affiliations": [
        "Hospital Morales Meseguer, Hospital Pharmacy, Murcia, Spain"
      ],
      "name": "B Cabezuelo Baldueza"
    },
    {
      "affiliations": [
        "Hospital Morales Meseguer, Hospital Pharmacy, Murcia, Spain"
      ],
      "name": "CM Gea Muñoz"
    },
    {
      "affiliations": [
        "Hospital Morales Meseguer, Hospital Pharmacy, Murcia, Spain"
      ],
      "name": "M Ventura Lopez"
    }
  ],
  "title": "5PSQ-052 Analysis of the frequency of administration of ranibizumab0.165 mg syringe and aflibercept3.6 mg syringe in age-related macular degeneration and diabetic macular oedema: resource management implications",
  "uid": "0b2ec643-9056-5558-9914-d0f39e405e73"
}